Fycompa Approved for Epileptic Seizures

MONDAY, Oct. 22 (HealthDay News) -- Fycompa (perampanel) tablets have been approved by the U.S. Food and Drug Administration to treat partial onset seizures in people aged 12 and older who have epilepsy.

Partial onset seizures are the most common seizures in people with epilepsy, a disorder commonly triggered by overactive nerve cells in the brain. Symptoms may include spasms, unusual behavior and loss of consciousness, the FDA said Monday in a news release.

The most common side effects of Fycompa reported during clinical trials included dizziness, sleepiness, irritability, falls, upper respiratory infections and weight gain.

Fycompa's label warns of the possibility of more serious side effects, including aggression, anger, anxiety, paranoia, euphoria and agitation.

The drug is produced by Eisai Inc., of Woodcliff Lake, N.J.

More information

The U.S. National Library of Medicine has more about epilepsy.

Related Articles

Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.

Health News is provided as a service to Sharp Web site users by HealthDay. Sharp HealthCare nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please read the Terms of Use for more information.